{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:35:09Z","timestamp":1761280509729,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent condition worldwide, occurring both independently and, more importantly, as the most common extraintestinal complication of inflammatory bowel disease (IBD). The study primarily investigated MASLD prevalence in Crohn\u2019s disease (CD) and ulcerative colitis (UC) to enhance prevention and early detection, especially given the recent approval of the first treatment for this condition. Secondary objectives included identifying risk factors, exploring the uric acid\/high-density lipoprotein cholesterol ratio (UHRatio) as a steatosis marker and evaluating correlations between non-invasive fibrosis scores, Fibrosis-4 (FIB-4), AST-to-Platelet Ratio Index (APRI), and histological fibrosis severity. We conducted a prospective study on 58 patients diagnosed with IBD. The type of IBD was not independently associated with liver steatosis or fibrosis. Disease activity correlated significantly with hepatic steatosis in CD patients and with hepatic fibrosis in UC patients. The UHRatio proved useful in assessing steatosis prevalence, whereas FIB-4 and APRI scores did not correlate significantly with fibrosis severity. This study is, to our knowledge, the first to evaluate UHRatio as a potential predictor of MASLD in patients with IBD, expanding on previous findings reported in the general population. Our results suggest that this non-invasive biomarker, previously used to identify MASLD, may improve early prediction and could serve as a useful screening tool for MASLD in IBD patients.<\/jats:p>","DOI":"10.3390\/ijms262110288","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:14:02Z","timestamp":1761182042000},"page":"10288","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Overlap of MASLD and IBD: Insights from a Single-Center Experience"],"prefix":"10.3390","volume":"26","author":[{"given":"Ana","family":"Stemate","sequence":"first","affiliation":[{"name":"Department of Gastroenterology 1, Emergency University Hospital, Splaiul Independen\u021bei Street, No. 169, Sector 6, 050098 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia-Ionela","family":"Negru-Vod\u0103","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Faculty of General Medicine, Dionisie Lupu Street, No. 37, Sector 2, 020021 Bucharest, Romania"},{"name":"Department of Gastroenterology 1, Emergency University Hospital, Splaiul Independen\u021bei Street, No. 169, Sector 6, 050098 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria Patricia","family":"Mazurencu-Pele","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Faculty of General Medicine, Dionisie Lupu Street, No. 37, Sector 2, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remus-Florin","family":"Popescu","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Faculty of General Medicine, Dionisie Lupu Street, No. 37, Sector 2, 020021 Bucharest, Romania"},{"name":"Department of Gastroenterology 1, Emergency University Hospital, Splaiul Independen\u021bei Street, No. 169, Sector 6, 050098 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teodora-Iulia","family":"Sp\u0103taru","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Faculty of General Medicine, Dionisie Lupu Street, No. 37, Sector 2, 020021 Bucharest, Romania"},{"name":"Department of Gastroenterology 1, Emergency University Hospital, Splaiul Independen\u021bei Street, No. 169, Sector 6, 050098 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-0754","authenticated-orcid":false,"given":"Lucian","family":"Negreanu","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Faculty of General Medicine, Dionisie Lupu Street, No. 37, Sector 2, 020021 Bucharest, Romania"},{"name":"Department of Gastroenterology 1, Emergency University Hospital, Splaiul Independen\u021bei Street, No. 169, Sector 6, 050098 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref_1","unstructured":"Yamada, T., and Alpers, D.H. (2009). Textbook of Gastroenterology, Blackwell Publishing. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Maresca, R., Mignini, I., Varca, S., Calvez, V., Termite, F., Esposto, G., Laterza, L., Scaldaferri, F., Ainora, M.E., and Gasbarrini, A. (2024). Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063278"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory Bowel Disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of Disease: Inflammatory Bowel Diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Saez, A., Herrero-Fernandez, B., Gomez-Bris, R., S\u00e1nchez-Martinez, H., and Gonzalez-Granado, J.M. (2023). Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021526"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2018.12.003","article-title":"Hepatic Complications of Inflammatory Bowel Disease","volume":"23","author":"Mahfouz","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/liv.13265","article-title":"Hepatic Manifestations of Inflammatory Bowel Diseases","volume":"37","author":"Restellini","year":"2017","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (MASLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A Position Statement on MASLD\/NASH Based on the EASL 2009 Special Conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.21037\/hbsn.2018.11.06","article-title":"Non-Alcoholic Fatty Liver Disease (MASLD) and the Quest for Effective Treatments","volume":"8","author":"Thanapirom","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zeigerer, A. (2021). MASLD\u2014A Rising Metabolic Disease. Mol. Metab., 50.","DOI":"10.1016\/j.molmet.2021.101274"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X11430859","article-title":"Secondary Causes of Nonalcoholic Fatty Liver Disease","volume":"5","author":"Kneeman","year":"2012","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Adams, L.C., L\u00fcbbe, F., Bressem, K., Wagner, M., Hamm, B., and Makowski, M.R. (2018). Non-Alcoholic Fatty Liver Disease in Underweight Patients with Inflammatory Bowel Disease: A Case-Control Study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206450"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography","volume":"25","author":"Palumbo","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.mayocp.2015.06.013","article-title":"Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of MASLD and NASH","volume":"90","author":"Spengler","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1155\/2012\/725468","article-title":"Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"26","author":"Beaton","year":"2012","journal-title":"Can. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Dom\u00ednguez, S.J., Garc\u00eda-Mateo, S., Laredo, V., Gargallo-Puyuelo, C.J., Gallego Llera, B., L\u00f3pez de la Cruz, J., and Gomoll\u00f3n, F. (2023). Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers, 15.","DOI":"10.3390\/cancers15133367"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Duan, Y., Li, J., and Luo, M. (2022). Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880298"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1177\/2047487318792952","article-title":"Inflammatory Bowel Disease and Cardiovascular Disease Incidence and Mortality: A Meta-Analysis","volume":"25","author":"Sun","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nasir, K., Acquah, I., Dey, A.K., Agrawal, T., Hassan, S.Z., Glassner, K., Abraham, B., Quigley, E.M.M., Blankstein, R., and Virani, S.S. (2022). Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease in U.S. Adults\u2014A Population-Level Analysis in the National Health Interview Survey. Am. J. Prev. Cardiol., 9.","DOI":"10.1016\/j.ajpc.2022.100316"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.31689\/rmm.2021.29.2.123","article-title":"Early Atherosclerosis and Acute Vascular Events in Ulcerative Colitis Patients\u2014A Case Series","volume":"29","author":"Negreanu","year":"2022","journal-title":"Mod. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1007\/s10620-020-06588-6","article-title":"Nonalcoholic Fatty Liver Disease Is Common in IBD Patients; However, Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare","volume":"66","author":"Ritaccio","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2019.11.003","article-title":"The Microbiome and Inflammatory Bowel Disease","volume":"145","author":"Glassner","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control TH17 and Treg cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Li, R., Andreu-S\u00e1nchez, S., Kuipers, F., Fu, J., Torres-Fuentes, C., Zheng, X., Su, J., Zhou, L., Hoekstra, M., and Fu, J. (2022). Bile Acids and Gut Microbiota in Inflammatory Bowel Disease. Front. Physiol., 13.","DOI":"10.3389\/fimmu.2022.974305"},{"key":"ref_27","first-page":"1418","article-title":"FXR and TGR5 in Metabolic-Associated Fatty Liver Disease","volume":"68","author":"Jiao","year":"2018","journal-title":"Hepatology"},{"key":"ref_28","first-page":"387","article-title":"Gut Microbial Metabolism and SCFA in Crohn\u2019s Disease","volume":"9","author":"Machiels","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_29","first-page":"49","article-title":"Intestinal Permeability and Liver Inflammation in Inflammatory Bowel Disease","volume":"14","author":"Mouzaki","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","first-page":"12","article-title":"Cross-Talk between Gut Inflammation and MASLD","volume":"17","author":"Yeh","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","article-title":"Cirrhosis-Associated Immune Dysfunction","volume":"19","author":"Albillos","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_32","first-page":"463","article-title":"High Prevalence of Non-Alcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease Receiving Anti-Tumor Necrosis Factor Therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Voss, J., Schneider, C.V., Kleinjans, M., Bruns, T., Trautwein, C., and Strnad, P. (2021). Hepatobiliary Phenotype of Individuals with Chronic Intestinal Disorders. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-98843-7"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"27","author":"Lin","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12794","article-title":"Systematic Review: The Epidemiology of the Hepatobiliary Manifestations in Patients with Inflammatory Bowel Disease","volume":"40","author":"Gizard","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s10620-022-07562-0","article-title":"Crohn\u2019s Disease Is Associated with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease","volume":"68","author":"Aggarwal","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Cross-Sectional and Longitudinal Analysis","volume":"26","author":"Hoffmann","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/ibd\/izy051","article-title":"Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors","volume":"24","author":"Principi","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Xie, Y., Huang, K., Zhang, X., Wu, Z., Wu, Y., Chu, J., Kong, W., and Qian, G. (2023). Association of Serum Uric Acid-to-High-Density Lipoprotein Cholesterol Ratio with Non-Alcoholic Fatty Liver Disease in American Adults: A Population-Based Analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1164096"},{"key":"ref_41","first-page":"2041","article-title":"Metabolic Dysfunction\u2014Associated Steatotic Liver Disease in Inflammatory Bowel Disease: Emerging Links and Preventive Strategies","volume":"21","author":"Khanna","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_42","first-page":"91","article-title":"Hepatic Steatosis in Inflammatory Bowel Disease: Pathogenesis, Clinical Significance, and Management","volume":"17","author":"Lazaridis","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/flgastro-2018-101037","article-title":"Practical Clinical Approach to the Evaluation of Hepatobiliary Disorders in Inflammatory Bowel Disease","volume":"10","author":"Yaccob","year":"2019","journal-title":"Frontline Gastroenterol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:29:51Z","timestamp":1761280191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":43,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ijms262110288"],"URL":"https:\/\/doi.org\/10.3390\/ijms262110288","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}